Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16874
Country/Region: Tanzania
Year: 2017
Main Partner: Tanzania Health Promotion Support
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,140,378 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $185,030
Care: Pediatric Care and Support (PDCS) $26,954
Strategic Information (HVSI) $250,000
Testing: HIV Testing and Counseling (HVCT) $471,342
Sexual Prevention: Other Sexual Prevention (HVOP) $68,432
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $289,208
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $448,770
Treatment: Adult Treatment (HTXS) $2,227,857
Treatment: Pediatric Treatment (PDTX) $172,785
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 2,690
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 2,367
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 2,690
GEND_GBV Number of people receiving post-GBV care 2018 5,057
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 459,728
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative 2018 242
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative 2018 242
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 352
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 775
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative 2018 59,188
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative 2018 7,192
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative 2018 7,191
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative 2018 28,434
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative 2018 13,040
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 37,125
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 37,128
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 179,034
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 71,555
HTS_TST Sum of Test Result disaggregates 2018 18,230
HTS_TST_POS By Test Result: Positive 2018 18,230
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive 2018 13
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 215
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 148
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive 2018 1,033
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive 2018 47
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive 2018 47
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive 2018 1,536
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive 2018 721
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 337
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 339
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 9,381
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 4,400
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2018 1,061
KP_MAT Sex: Female 2018 272
KP_MAT Sex: Male 2018 789
KP_MAT Sum of Sex disaggregates 2018 1,061
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 2,001
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 106
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 1,221
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 325
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 3,653
PMTCT_ART Already on ART at beginning of current pregnancy 2018 682
PMTCT_ART New on ART 2018 1,348
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 2,030
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 61,316
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 2,025
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 323
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 1,649
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 8
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 45
PMTCT_STAT By Age (Numerator): Unknown Age 2018 61,314
PMTCT_STAT By Number of known positives: Unknown Age 2018 1,094
PMTCT_STAT By Number of new negative: Unknown Age 2018 59,188
PMTCT_STAT By Number of new positives: Unknown Age 2018 1,033
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 61,316
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 65,173
PP_PREV Age/sex: 20-24 Female 2018 120
PP_PREV Age/sex: 20-24 Male 2018 211
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 331
PP_PREV Sum of Age/Sex disaggregates 2018 331
TB_PREV By Age/Sex (Numerator): <15, Female 2018 327
TB_PREV By Age/Sex (Numerator): <15, Male 2018 216
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 3,035
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 2,029
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 5,607
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 5,607
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 10,937
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 646
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 437
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 5,908
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 3,946
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 10,937
TX_CURR Age/Sex: <1-9 2018 10
TX_CURR Age/Sex: 10-14 Female 2018 9
TX_CURR Age/Sex: 10-14 Male 2018 4
TX_CURR Age/Sex: 15-19 Female 2018 5
TX_CURR Age/Sex: 15-19 Male 2018 4
TX_CURR Age/Sex: 20-24 Female 2018 8
TX_CURR Age/Sex: 20-24 Male 2018 2
TX_CURR Age/Sex: 25-49 Female 2018 105
TX_CURR Age/Sex: 25-49 Male 2018 55
TX_CURR Age/Sex: 50+ Female 2018 34
TX_CURR Age/Sex: 50+ Male 2018 31
TX_CURR Aggregated Age/Sex: <15 Female 2018 2,137
TX_CURR Aggregated Age/Sex: <15 Male 2018 2,004
TX_CURR Aggregated Age/Sex: 15+ Female 2018 43,368
TX_CURR Aggregated Age/Sex: 15+ Male 2018 16,830
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 64,611
TX_CURR Sum of age/sex disaggregates 2018 9
TX_CURR Sum of Aggregated Age/Sex <15 2018 4,141
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 60,198
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 64,339
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 601
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 491
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 12,660
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 5,192
TX_NEW By Age/Sex: 20-24 Female 2018 1
TX_NEW By Age/Sex: 25-49 Male 2018 1
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 18,949
TX_NEW Pregnancy status 2018 1,344
TX_NEW Sum of Age/Sex disaggregates 2018 2
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 18,944
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 48,385
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 43,478
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,299
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 144
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 1,224
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 137
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 26,470
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 2,937
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 10,138
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 1,126
TX_PVLS Numerator: Indication: Routine 2018 39,129
TX_PVLS Numerator: Indication: Targeted 2018 4,349
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,446
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 153
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 1,349
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 146
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 29,080
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 3,236
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 11,193
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 1,254
TX_PVLS_den Denominator: Indication: Routine 2018 43,544
TX_PVLS_den Denominator: Indication: Targeted 2018 4,835
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 517
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 413
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 10,756
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 4,412
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 16,105
TX_RET Numerator by Status: Pregnant 2018 1,151
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 18,941
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 597
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 490
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 12,536
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 5,313
TX_RET_den Denominator by Status: Pregnant 2018 1,341
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 61,405
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 1,535
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 82
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 55
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 864
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 534
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 3,685
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 2,462
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 33,179
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 22,079
TX_TB_den Denominator: By Screen Result: Negative 2018 59,881
TX_TB_den Denominator: By Screen Result: Positive 2018 1,524